---
title: "Novartis' fourth-quarter core earnings per share exceeded expectations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/226748691.md"
description: "Novartis' core earnings per share for the fourth quarter were $1.98, exceeding the estimated $1.82. Core operating profit was $4.86 billion, estimated at $4.44 billion; core net profit was $3.93 billion, estimated at $3.61 billion. Net sales were $13.15 billion, estimated at $12.88 billion. Cosentyx sales were $1.6 billion, slightly below the estimated $1.67 billion; Entresto sales were $2.18 billion, above the estimated $2.03 billion"
datetime: "2025-01-31T06:01:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/226748691.md)
  - [en](https://longbridge.com/en/news/226748691.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/226748691.md)
generator: "portal-rs"
---

# Novartis' fourth-quarter core earnings per share exceeded expectations

Novartis' core earnings per share for the fourth quarter were $1.98, estimated at $1.82.  
 Core operating profit for the fourth quarter was $4.86 billion, estimated at $4.44 billion.  
 Core net profit for the fourth quarter was $3.93 billion, estimated at $3.61 billion.  
 Net sales for the fourth quarter were $13.15 billion, estimated at $12.88 billion.  
 Sales of Cosentyx for the fourth quarter were $1.60 billion, estimated at $1.67 billion.  
 Sales of Entresto for the fourth quarter were $2.18 billion, estimated at $2.03 billion

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [603538.CN](https://longbridge.com/en/quote/603538.CN.md)
- [603456.CN](https://longbridge.com/en/quote/603456.CN.md)
- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)

## Related News & Research

- [Should Multiple Sclerosis Trial Win Require Action From Novartis (SWX:NOVN) Investors?](https://longbridge.com/en/news/299092670.md)
- [BREAKINGVIEWS-For Novartis, M&A is both a disease and cure](https://longbridge.com/en/news/298726698.md)
- [Novartis RNA drug falls short in rare muscle disease study](https://longbridge.com/en/news/298589584.md)
- [Novartis DM1 Trial Setback Offset by Progress in Neuromuscular Pipeline](https://longbridge.com/en/news/298303140.md)
- [Key facts: Novartis posts late-stage failures; keeps 5-6% CAGR](https://longbridge.com/en/news/298276336.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**